ISTH AWARD丨Pioneer in Platelet Research Shaping the Future of Hematology: Dr. Andreas Greinacher Receives the Grant Medal

ISTH AWARD丨Pioneer in Platelet Research Shaping the Future of Hematology: Dr. Andreas Greinacher Receives the Grant Medal

Dr. Andreas Greinacher, with over 35 years of extensive experience, has brought groundbreaking scientific discoveries to the field of hematology through his critical thinking and relentless curiosity. At the highly anticipated 2024 International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting, he was awarded the prestigious Robert P. Grant Medal, showcasing his profound expertise and significant contributions to the field of thrombosis and hemostasis.
ISTH Award丨Pioneer in Hematology: Dr. David Lillicrap Receives the Harold R. Roberts Award

ISTH Award丨Pioneer in Hematology: Dr. David Lillicrap Receives the Harold R. Roberts Award

The International Society on Thrombosis and Haemostasis (ISTH) is an inclusive organization with a global perspective, providing a valuable platform for scholars from around the world to engage, interact, and collaborate. Dr. David Lillicrap, a professor in the Department of Pathology and Molecular Medicine at Queen's University in Canada, was honored with the Harold R. Roberts Award at the ISTH 2024 meeting. This award recognizes individuals who have steadfastly supported the mission of the ISTH Scientific and Standardization Committee (SSC) through selfless dedication and expertise. As an outstanding hematologist and researcher, Dr. Lillicrap enjoys high acclaim in the field and has held several leadership positions within ISTH, including the Chair of the ISTH SSC. The Roberts Award not only acknowledges his exceptional service to the ISTH SSC but also celebrates his extraordinary dedication and lasting contributions.
ISTH AWARD丨2024 Fundamental Research Career Development Award Winners in Hematology

ISTH AWARD丨2024 Fundamental Research Career Development Award Winners in Hematology

The International Society on Thrombosis and Haemostasis (ISTH) announced the winners of the 2024 Fundamental Research Career Development Awards at the conference. This award aims to recognize early-career researchers who have made outstanding achievements in basic research. By acknowledging and encouraging these young scientists' innovative ideas, ISTH hopes to support them on their path to independent research, thereby strengthening the field of basic research. Each awardee will receive a grant to support their research, training, and collaborative studies in their respective fields. This award program, meticulously planned by the ISTH Fundamental Research Working Group under the guidance of the Education Committee, is designed as a career development incentive for promising early-career researchers.
CDL·Issue 18

CDL·Issue 18

Diabetes and liver disease are common chronic diseases in China. They interact with each other in terms of pathogenesis, clinical manifestations, and therapeutic targets, often serving as mutual risk factors. Effective co-management can help reduce the disease burden. To support the development of diabetes and liver disease co-management in China, this journal, in collaboration with the China Diabetes and Liver Disease Co-Management Initiative (CDL), presents the CDL Literature Monthly Review. Each month, we share relevant literature on the mechanisms of disease, diagnostic and therapeutic advancements concerning diabetes combined with liver disease, and invite experts in the field to provide commentary. We hope this review offers valuable insights and assistance to researchers, clinical practitioners, and front-line medical workers engaged in scientific research and clinical treatment.
Chinese guidelines on the management of ascites in cirrhosis

Chinese guidelines on the management of ascites in cirrhosis

In 2023, the Chinese Society of Hepatology of the Chinese Medical Association updated the 2017 guidelines on managing ascites and associated complications in cirrhosis. These revised guidelines, now termed "Guidelines on the Management of Ascites in Cirrhosis," provide comprehensive recommendations for the diagnosis and treatment of cirrhotic ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS). This article summarizes these guidelines, emphasizing the importance of evidence-based practices and individualized patient care.
2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Jiayi Chen

2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Jiayi Chen

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province People's Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.
2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Man Li

2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Man Li

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.
2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Yingying Xu

2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Yingying Xu

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province People's Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.
The 8th Yunnan Breast Cancer Summit Forum | Dr. Zhaoqing Fan: Overview of HR+/HER2- Breast Cancer Treatment Landscape and Prospects of Immunotherapy in Early-Stage Patients

The 8th Yunnan Breast Cancer Summit Forum | Dr. Zhaoqing Fan: Overview of HR+/HER2- Breast Cancer Treatment Landscape and Prospects of Immunotherapy in Early-Stage Patients

On July 14, the "8th Yunnan Breast Cancer Summit Forum" was held in Kunming, coinciding with the 40th anniversary of the Yunnan Cancer Hospital. This event, organized by the Yunnan Anti-Cancer Association and the China Medical Education Association, and co-hosted by eight institutions including the Peking University Cancer Hospital Yunnan Branch, Yunnan Cancer Hospital, and the Third Affiliated Hospital of Kunming Medical University, brought together the latest advances in breast cancer. At the conference, "Oncology Frontier" invited Dr. Zhaoqing Fan from Peking University Cancer Hospital to provide an overview of the treatment landscape for HR+/HER2- breast cancer and to discuss the prospects of immunotherapy in early-stage patients based on the CheckMate 7FL and KEYNOTE-756 studies, guiding the future direction of new drug development for neoadjuvant therapy.
Evaluation of the Efficacy and Safety of Entrectinib Targeted Therapy for ROS1 Fusion Detected in Peripheral Blood

Evaluation of the Efficacy and Safety of Entrectinib Targeted Therapy for ROS1 Fusion Detected in Peripheral Blood

The development of modern oncology has provided multiple breakthrough treatment options for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians comprehensively grasp the significant advancements in this field, "Oncology Frontier" collaborates with Dr. Hua Zhong and Dr. Baohui Han from the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital, Shanghai JiaoTong University School of Medicine, to present the clinical progress series "Zhong" Sound "Hui" Words. Through high-quality interpretations of clinical research in lung cancer, this series aims to enhance clinical practice. In the 22nd episode, the Dr. present "Evaluation of the Efficacy and Safety of Entrectinib Targeted Therapy for ROS1 Fusion Detected in Peripheral Blood," based on data from the BFAST clinical study's D cohort, recently published in Nature Medicine.